YIDU TECH (02158) wins a bid for a 7.39 million yuan AI medical order. Recently, it has been awarded multiple top medical institution projects.

The pace of winning bids in YIDU TECH's (02158) AI medical project has noticeably accelerated. Following the successful acquisition of heavyweight projects such as Sun Yat-sen University Cancer Center and Singapore SingHealth, this leading AI medical company has once again secured a core order from a top specialized cancer hospital. On May 21st at noon, YIDU TECH released a voluntary announcement, stating that its affiliate company, MedLinker Cloud (Beijing) Technology Co., Ltd., won the bid for the construction of an intelligent clinical research integrated platform project at Tianjin Cancer Hospital, with a total amount of approximately 7.39 million RMB. This is the eighth bid announcement made by YIDU TECH since April. With orders intensively landing, customer repeat purchases become the main theme. Recent announcements show that YIDU TECH's orders exhibit two major characteristics: high density and high repeat purchase rate. From April to present, the projects successively disclosed by YIDU TECH include: The PIONEER2 clinical trial SMO project at the First Affiliated Hospital of Guangzhou Medical University, the construction project of Hainan Smart Health Island (approximately 14.76 million RMB), the second phase of Hainan Provincial Infectious Disease Monitoring and Early Warning Platform (approximately 12.89 million RMB), the AI construction cooperation project with Beijing Cancer Hospital (approximately 4.88 million RMB), the intelligent clinical upgrade project at Sun Yat-sen University Cancer Hospital (approximately 9.08 million RMB), Singapore SingHealth Dr Buddy project (approximately 12.20 million RMB), and the hospital-wide data center and informatization project at Fuling Hospital of Chongqing University (approximately 9.65 million RMB), among others. It is worth noting that multiple projects come from deep repeat purchases by old customers. For example, the project with Sun Yat-sen University Cancer Center has been in cooperation since 2015, progressing from the construction of a big data platform to the private deployment of the AI middle platform, and now to the nearly million-dollar intelligent clinical upgrade project, showing a continuous deepening collaboration. The project with the First Affiliated Hospital of Guangzhou Medical University is also an extension of the PIONEER series of studies, achieving a deep binding with core customers. With the confirmation of the turning point in profitability, the initial closure of the commercialization loop Behind the intensively landing orders is a substantial breakthrough in YIDU TECH's commercial capabilities. On April 20th, the company announced a positive profit forecast, estimating that the net profit for the fiscal year 2026 (ending on March 31, 2026) will reach 55 to 70 million RMB, marking the first time the company has achieved an annual turnaround from loss to profit in its 11-year history. This turning point is attributed to the growth in orders and gross profit margin improvement brought by the integration of the company's AI products into clinical workflows. According to the company's interim performance disclosure, its AI middle platform has been implemented in more than 40 Grade A tertiary hospitals, with the Doctor Copilot app achieving nearly a thousand high-frequency calls per day in a single hospital, and YiduCore processing and analyzing nearly 7 billion medical records. At the recent CHIMA 2026 conference, the company further released the AI Hospital solution, covering the development of medical intelligent entities, the new generation operation data center, and other product matrices. From top Grade A tertiary hospitals in Beijing and Guangzhou, to provincial public health platforms in Hainan, to national-level projects in Singapore, YIDU TECH is forming a positive cycle of "technology upgrade - order growth - performance reversal". As the AI medical industry shifts from "model deployment" to "running commercialization", this leading profitable enterprise is standing at a key node in the industry reshuffle.